1. Scrip

Hong Kong's First 2022 Biotech IPO Debuts

Plus Other Broad Funding Across Modalities

 
• By Dexter Jie Yan

One IPO on the Hong Kong Stock Exchange and seven venture capital or private equity deals raised a combined $329m in China in February.

fund raising
VC/PE investors continued injecting capitals into Chinese biotechs, and small molecule developers obtained the largest share. • Source: Alamy

Shanghai-based immuno-oncology developer Lepu Biopharma went public on 23 February, becoming the first biotech to be listed in 2022 on the Hong Kong Stock Exchange.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia